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Abstract
Human blood Vc9/Vd2 T cells, monocytes and neutrophils share a responsiveness toward inflammatory chemokines and are
rapidly recruited to sites of infection. Studying their interaction in vitro and relating these findings to in vivo observations in
patients may therefore provide crucial insight into inflammatory events. Our present data demonstrate that Vc9/Vd2 T cells
provide potent survival signals resulting in neutrophil activation and the release of the neutrophil chemoattractant CXCL8
(IL-8). In turn, Vc9/Vd2 T cells readily respond to neutrophils harboring phagocytosed bacteria, as evidenced by expression
of CD69, interferon (IFN)-c and tumor necrosis factor (TNF)-a. This response is dependent on the ability of these bacteria to
produce the microbial metabolite (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), requires cell-cell contact of
Vc9/Vd2 T cells with accessory monocytes through lymphocyte function-associated antigen-1 (LFA-1), and results in a TNF-a
dependent proliferation of Vc9/Vd2 T cells. The antibiotic fosmidomycin, which targets the HMB-PP biosynthesis pathway,
not only has a direct antibacterial effect on most HMB-PP producing bacteria but also possesses rapid anti-inflammatory
properties by inhibiting cd T cell responses in vitro. Patients with acute peritoneal-dialysis (PD)-associated bacterial
peritonitis – characterized by an excessive influx of neutrophils and monocytes into the peritoneal cavity – show a selective
activation of local Vc9/Vd2 T cells by HMB-PP producing but not by HMB-PP deficient bacterial pathogens. The cd T cell-
driven perpetuation of inflammatory responses during acute peritonitis is associated with elevated peritoneal levels of cd T
cells and TNF-a and detrimental clinical outcomes in infections caused by HMB-PP positive microorganisms. Taken together,
our findings indicate a direct link between invading pathogens, neutrophils, monocytes and microbe-responsive cd T cells
in early infection and suggest novel diagnostic and therapeutic approaches.
Citation: Davey MS, Lin C-Y, Roberts GW, Heuston S, Brown AC, et al. (2011) Human Neutrophil Clearance of Bacterial Pathogens Triggers Anti-Microbial cd T Cell
Responses in Early Infection. PLoS Pathog 7(5): e1002040. doi:10.1371/journal.ppat.1002040
Editor: E. John Wherry, University of Pennsylvania, United States of America
Received December 5, 2010; Accepted March 11, 2011; Published May 12, 2011
Copyright:  2011 Davey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by Welsh Assembly Government project grants H07-03-18 (ME and NT) and HA09-009 (GWR, ME and NT) and by Baxter
Healthcare Renal Discoveries extramural grant #08AP002 (ME, JDW and CYL). BM was in receipt of a Royal Society Wolfson Research Merit Award; ME was in
receipt of a RCUK Fellowship in Translational Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: eberlm@cf.ac.uk
. These authors contributed equally to this work.
Introduction
The cellular immune system consists of an ‘innate’ arm of
phagocytes and antigen-presenting cells, and an ‘adaptive’ arm of
antigen-specific lymphocytes capable of developing immunological
memory. Yet, there is increasing evidence of considerable crosstalk
between the two [1]. Innate responses directly influence the shape
and outcome of adaptive T cell responses, and vice versa specialized
T cell subsets feedback to innate cells [2]. Among these
interactions, the regulation of neutrophil-mediated inflammatory
responses by Th17 cells has received enormous attention over the
past few years [3], and with the emergence of novel T cell subsets
additional networks are being proposed so that each polarized T
cell eventually pairs with an innate counter player [4–7].
The necessity to integrate complex signals in order to mount the
most effective defense is best illustrated by the existence of
‘unconventional’ T cells bridging the classical divide between
innate and adaptive immunity, such as natural killer T cells,
mucosal-associated invariant T cells, intestinal intraepithelial
CD8aa+ T cells and dendritic epidermal cd T cells [8–14]. These
often tissue-associated lymphocytes are characterised by restricted
T cell receptor (TCR) repertoires that allow them to respond
rapidly to a limited range of conserved structures. Unconventional
T cells readily assume a plethora of effector functions, ranging
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from sentinel tasks and targeted killing to engaging with
keratinocytes, fibroblasts, phagocytes and antigen-presenting cells
as well as other lymphocyte.
cd T cells expressing a Vc9/Vd2 TCR – Vc2/Vd2 according
to an alternative nomenclature – are only found in humans and
higher primates and differ fundamentally from all other conven-
tional and unconventional T cells [15]. Activated Vc9/Vd2 T cells
produce a range of cytokines, kill infected and transformed target
cells, regulate survival and differentiation of monocytes and
maturation of dendritic cells, provide B cell help and present
antigens to CD4+ and CD8+ T cells [11,12,16,17]. They expand
considerably in many infections, at times to .50% of all
circulating T cells within a few days [18], and respond selectively
in a non-MHC restricted manner to the microbial metabolite (E)-
4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) [19].
HMB-PP is an intermediate of the non-mevalonate pathway of
isoprenoid biosynthesis that is present in many bacteria and in
malaria parasites but not in humans [17–19]. The rapid and
sensitive response of Vc9/Vd2 T cells to a broad range of
pathogens evokes cardinal features of innate immunity. Indeed,
HMB-PP fulfills Janeway’s criteria for a ‘pathogen-associated
molecular pattern’ in that it is (i) invariant among different species;
(ii) a product of a pathway unique to micro-organisms; and (iii)
essential in microbial physiology [17]. Yet, HMB-PP recognition is
not mediated via germline-encoded pattern recognition receptors
but involves the re-arranged Vc9/Vd2 TCR [20–22].
Bacteria that possess the non-mevalonate pathway and hence
produce HMB-PP comprise some of the most detrimental human
pathogens such as the causative agents of cholera, diphtheria,
plague, tuberculosis and typhoid, but also numerous commensal
and opportunistic species in the mucosal flora, skin and feces
[19,23]. In all these micro-organisms, HMB-PP is an essential
intracellular metabolite, and it is not clear whether and how it is
released by invading bacteria and becomes visible to the immune
system as soluble molecule. Indeed, earlier studies with mycobac-
teria suggested that uptake of whole bacteria by monocytes,
macrophages, or DCs may be required for the recognition by
Vc9/Vd2 T cells [24–27]. Neutrophils are the first immune cells
infiltrating the site of infection and the main phagocytes
responsible for early pathogen clearance, and growing evidence
points toward a crucial role of cd T cells in regulating neutrophil
responses in mouse models of infection, hypersensitivity and
autoimmunity [8,12]. Yet, the interplay between cd T cells and
neutrophils has not been addressed in detail [28,29]. Our present
data demonstrate that Vc9/Vd2 T cells readily respond to
neutrophils harboring phagocytosed bacteria, and that this
response is strictly dependent on the ability of these bacteria to
produce HMB-PP and cell-cell contact of Vc9/Vd2 T cells with
accessory monocytes. The majority of circulating Vc9/Vd2 T cells
shows migration properties similar to monocytes [30], suggesting
that these two cell types are co-recruited to the site of
inflammation and interact with each other at early stages of
infection [17,31]. Our present findings thus indicate a direct link
between invading pathogens, neutrophils, monocytes and
microbe-responsive cd T cells, and suggest novel diagnostic and
therapeutic approaches in acute infection.
Results
Human cd T cells induce neutrophil survival and
activation
Neutrophils are short-lived phagocytes that undergo spontane-
ous apoptosis in vitro unless rescued by survival signals. We
previously demonstrated that activated human Vc9/Vd2 T cells
induce monocytes to survive and differentiate into inflammatory
dendritic cells [31]. Here, HMB-PP stimulated Vc9/Vd2 T cells
had a similar survival effect on autologous neutrophils and readily
rescued them from undergoing apoptosis (Figure 1). This effect
was selective and dependent on the number of Vc9/Vd2 T cells
and the concentration of HMB-PP. An increase in neutrophil
survival could already be observed at ratios of only 1 cd T cell per
100 neutrophils and at HMB-PP concentrations as low as 0.1–
1 nM. Activation of Vc9/Vd2 T cells in these cultures was
confirmed by upregulation of CD69 and secretion of interferon
(IFN)-c (Figure S1 in Text S1). The low cd T cell numbers and
HMB-PP concentrations needed to promote neutrophil survival in
vitro are likely to have physiologic relevance.
Activated neutrophils mobilize intracellular stores of CD11b to
the cell surface and shed CD62L, thus enhancing their potential to
undergo firm adhesions with endothelial cells and extravasate at
the site of inflammation. In line with their anti-apoptotic effect on
neutrophils, Vc9/Vd2 T cells induced upregulation of CD11b and
loss of CD62L in surviving neutrophils in an HMB-PP dependent
manner (Figure 2A). Importantly, synthetic HMB-PP alone did
not have any activity on neutrophils in the absence of cd T cells
(Figure 1, Figure 2 and data not shown).
Rapid recruitment of neutrophils involves the chemotactic
action of CXCL8 (IL-8) produced at the site of inflammation, and
increased endothelial permeability mediated by tumor necrosis
factor (TNF)-a. Analysis of the supernatants from the above
experiments revealed that co-cultures of neutrophils and HMB-PP
stimulated Vc9/Vd2 T cells produced considerable amounts of
both CXCL8 and TNF-a, in a dose-dependent manner and at
levels comparable to lipopolysaccharide (LPS) stimulated neutro-
phils (Figure 2B). Another cytokine implicated in neutrophil
recruitment is IL-17, which in a number of infection models is
readily produced by murine cd T cells [8]. While activated Vc9/
Vd2 T cells readily produce TNF-a, IFN-c and granulocyte/
macrophage colony-stimulating factor (GM-CSF) [31,32], we were
unable to detect IL-17 in our co-cultures indicating that under the
conditions tested human cd T cells failed to secrete relevant levels
of IL-17 (data not shown). This is reminiscent of recent findings
Author Summary
The immune system of all jawed vertebrates harbors three
distinct lymphocyte populations – ab T cells, cd T cells and
B cells – yet only higher primates including humans
possess so-called Vc9/Vd2 T cells, an enigmatic cd T cell
subset that uniformly responds to the majority of bacterial
pathogens. For reasons that are not understood, this
responsiveness is absent in all other animals although they
too are constantly exposed to a plethora of potentially
harmful micro-organisms. We here investigated how Vc9/
Vd2 T cells respond to live microbes by mimicking
physiological conditions in acute disease. Our experiments
demonstrate that Vc9/Vd2 T cells recognize a small
common molecule released when invading bacteria
become ingested and killed by other white blood cells.
The stimulation of Vc9/Vd2 T cells at the site of infection
amplifies the inflammatory response and has important
consequences for pathogen clearance and the develop-
ment of microbe-specific immunity. However, if triggered
at the wrong time or the wrong place, this rapid reaction
toward bacteria may also lead to inflammation-related
damage. These findings improve our insight into the
complex cellular interactions in early infection, identify
novel biomarkers of diagnostic and predictive value and
highlight new avenues for therapeutic intervention.
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that human ab T cells including human Th17 cells modulate
neutrophils (which lack the IL-17 receptor C chain) in an IL-17–
independent manner through a combination of TNF-a, IFN-c and
GM-CSF [33]. In our cultures, blocking experiments demonstrat-
ed that TNF-a played a key role in the cd T cell-mediated effect
on neutrophils, as judged by a partial inhibition of neutrophil
survival and a reduction of CD11b expression in the presence of
soluble TNF-a receptor (sTNFR), while neutralizing antibodies
against GM-CSF and IFN-c had no significant effect (Figure 3).
Taken together, these data show that Vc9/Vd2 T cells become
activated by soluble HMB-PP in the presence of autologous
neutrophils and that they provide potent stimulatory signals
inducing neutrophil survival and activation. The interaction of the
two cell types leads to the rapid release of the pro-inflammatory
mediators CXCL8 and TNF-a into the microenvironment,
thereby potentially maintaining neutrophil influx at the site of
infection.
Vc9/Vd2 T cells respond to neutrophils harboring
phagocytosed bacteria
Under physiological conditions, invading pathogens are rapidly
taken up by newly recruited neutrophils. We therefore tested
whether Vc9/Vd2 T cells respond to neutrophils harboring
phagocytosed bacteria in a similar manner as they respond to
soluble HMB-PP. In order to do this, we set up triple cultures
consisting of neutrophils, monocytes and Vc9/Vd2 T cells,
mimicking physiological conditions at the site of infection.
Human neutrophils readily took up green fluorescent protein
(GFP) expressing Escherichia coli, Listeria innocua and Mycobacterium
smegmatis, with .95% of the neutrophils being GFP+ within
30 min (Figure 4A and data not shown). Triple co-cultures of
neutrophils harboring different strains of M. smegmatis with
autologous Vc9/Vd2 T cells and monocytes led to rapid cd T
cell activation, as evidenced by upregulation of CD69 and
expression of TNF-a and IFN-c within 20 hours (Figure 4B and
data not shown). Activation profiles were similar to those seen in
control cultures with non-infected neutrophils in the presence of
synthetic HMB-PP, demonstrating that Vc9/Vd2 T cells respond
to bacterial degradation products released or presented by
neutrophils. For the sake of clarity and simplicity all activation
data in the following sections are shown as proportion of CD69+
TNF-a+ cd T cells in the cultures although the cells were always
co-stained for IFN-c as well. The proportion of CD69+ IFN-c+
and TNF-a+ IFN-c+ cd T cells followed essentially the same
pattern throughout this study and led to the same conclusions.
The Vc9/Vd2 T cell response to phagocytosed bacteria
depends on the ability of bacteria to produce HMB-PP
In order to investigate the correlation between the ability of
bacteria to produce HMB-PP and their capacity to stimulate Vc9/
Vd2 T cells, we designed experiments to distinguish a specific cd T
cell response to HMB-PP from a possible background stimulation
by the plethora of other microbial compounds acting via pattern
recognition receptors. Thus, we generated a M. smegmatis
transfectant stably expressing a second copy of the gene encoding
HMB-PP synthase (gcpE) and hence overproducing HMB-PP
compared to the parental wildtype (wt) strain [34] (Figure S2 in
Text S1). As a second bacterial model we utilized HMB-PP
producing and HMB-PP deficient strains of the non-pathogenic
Gram-positive bacterium Listeria innocua [35,36] (Figure S3 in Text
S1).
Compared with M. smegmatis wt bacteria, higher levels of Vc9/
Vd2 T cell activation were observed when using M. smegmatis-gcpE+
(Figure 5). Furthermore, considerable Vc9/Vd2 T cell activation
was seen with phagocytosed L. innocua-gcpE+, a strain in which
HMB-PP artificially accumulates, but not with the naturally
HMB-PP deficient L. innocua wt strain that was .1006 less potent
(Figure 5). The double transfectant L. innocua-gcpE+lytB+, in which
HMB-PP becomes converted into the downstream reaction
products isopentenyl pyrophosphate (IPP) and dimethylallyl
pyrophosphate (DMAPP), resulted in no detectable Vc9/Vd2 T
cell activation (data not shown). These data demonstrate that the
Figure 1. HMB-PP stimulated Vc9/Vd2 T cells induce neutrophil survival. Dose-dependent survival of neutrophils incubated with LPS, and of
neutrophils (PMN) co-cultured with Vc9/Vd2 T cells at various ratios in the presence of HMB-PP at different concentrations. Neutrophils were analyzed
after 20 hours in culture; dot plots depict representative annexin-V and fixable live/dead stainings for live CD32 CD15+ neutrophils cultured under
the indicated conditions. Data shown are mean percentages (%) + SEM of live cells from independent experiments using three different donors.
doi:10.1371/journal.ppat.1002040.g001
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response of Vc9/Vd2 T cells to neutrophils harboring phagocy-
tosed bacteria depends on the ability of these bacteria to produce
HMB-PP and suggest that phagocytosis and subsequent degrada-
tion of bacteria in neutrophils leads to either presentation of
HMB-PP on the cell surface or the release of soluble HMB-PP into
the microenvironment.
Crosstalk with monocytes provides essential help for the
Vc9/Vd2 T cell response to phagocytosed bacteria
Vc9/Vd2 T cells, monocytes and neutrophils share a
responsiveness toward inflammatory chemokines and are the
earliest leukocytes recruited to sites of infection. Vc9/Vd2 T cell
responses in vitro are greatly facilitated by contact with monocytes
as ‘feeder cells’, which most likely act by ‘presenting’ HMB-PP to
Vc9/Vd2 T cells and by providing contact-dependent signals [17].
In support of our previous observation of a substantial HMB-PP
dependent crosstalk between Vc9/Vd2 T cells and monocytes
leading to optimum cd T cell activation [31], the response of Vc9/
Vd2 T cells to neutrophils harboring phagocytosed L. innocua-gcpE+
was largely dependent on the presence of monocytes. Omission of
monocytes from the co-cultures resulted in greatly reduced
expression levels of CD69, TNF-a and IFN-c, compared to triple
co-cultures (Figure 6A and data not shown), suggesting that
monocytes provide essential help for the recognition of bacteria by
Vc9/Vd2 T cells and increase the sensitivity of the response
especially at low HMB-PP concentrations.
We speculated that this accessory effect might have stemmed
from contact-dependent interactions of monocytes with either
neutrophils or cd T cells and tested this hypothesis in transwell
cultures where neutrophils harboring phagocytosed L. innocua-
gcpE+ in the lower chamber were separated from Vc9/Vd2 T cells
in the upper chamber. As shown in Figure 6B, cell-cell contact
between monocytes and Vc9/Vd2 T cells was crucial for the
response to phagocytosed bacteria, while no contact was needed
between Vc9/Vd2 T cells and neutrophils, and neither between
Figure 2. HMB-PP stimulated Vc9/Vd2 T cells induce neutrophil
activation and production of pro-inflammatory mediators. (A)
Dose-dependent up-regulation of CD11b and shedding of CD62L by
neutrophils incubated with LPS as positive control, and of neutrophils
co-cultured with Vc9/Vd2 T cells at various ratios in the presence of
HMB-PP at different concentrations. Neutrophils were analyzed after
20 hours in culture; histograms depict representative CD11b and CD62L
stainings for live CD32 CD15+ neutrophils cultured under the indicated
conditions. Data shown are mean fluorescence intensities (MFI) + SEM
from independent experiments using three different donors. (B) Dose-
dependent secretion of CXCL8 and TNF-a into the culture supernatant
of neutrophils incubated with LPS as positive control, and of
neutrophils co-cultured with Vc9/Vd2 T cells at various ratios in the
presence of HMB-PP at different concentrations. Supernatants were
analyzed after 20 hours by ELISA. Data shown are mean levels (pg/ml) +
SEM from independent experiments using three different donors.
doi:10.1371/journal.ppat.1002040.g002
Figure 3. HMB-PP stimulated Vc9/Vd2 T cells induce neutrophil
survival and activation through TNF-a. Neutrophils were co-
cultured with Vc9/Vd2 T cells for 20 hours at a ratio of 5:1, in the
absence or presence of 10 nM HMB-PP. Soluble cytokines were blocked
by the addition of sTNFR, anti-GM-CSF or anti-IFN-c. Data shown are
mean values + SEM for neutrophil survival and expression of CD11b by
live neutrophils, as determined in independent experiments using three
different donors.
doi:10.1371/journal.ppat.1002040.g003
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monocytes and neutrophils. These data indicate that upon
phagocytosis of HMB-PP+ bacteria, neutrophils release soluble
factors that efficiently stimulate Vc9/Vd2 T cells, while monocytes
provide important contact-dependent accessory signals.
Upon phagocytosis of HMB-PP+ bacteria neutrophils
release HMB-PP into the culture supernatant
Since neutrophils harboring bacteria were able to stimulate
Vc9/Vd2 T cells in a transwell system, we next examined whether
cell-free culture supernatants derived from infected neutrophils
stimulated Vc9/Vd2 T cells in a similar manner. Indeed, Vc9/
Vd2 T cells readily responded to supernatants from neutrophils
harboring L. innocua-gcpE+ but not from neutrophils harboring L.
innocua wt bacteria, as evidenced by expression of CD69, TNF-a
and IFN-c (Figure 6C and data not shown). Importantly, short-
term pre-treatment of L. innocua-gcpE+ supernatants with shrimp
alkaline phosphatase abrogated the bioactivity on Vc9/Vd2 T
cells completely (Figure 6C), evoking the known sensitivity of
mycobacterial HMB-PP to dephosphorylation and the relative
inactivity of the dephosphorylated products [37–39]. Control
experiments confirmed that alkaline phosphatase affected the
response of Vc9/Vd2 T cells to synthetic HMB-PP but not to the
phosphatase-resistant diphosphonate analogue, HMB-PCP [40],
demonstrating that the presence of alkaline phosphatase in the
cultures had no inhibitory effect on the cells’ ability to express
CD69, TNF-a and IFN-c (Figure 6D and data not shown). We
conclude that upon phagocytosis of HMB-PP+ bacteria neutro-
phils release soluble HMB-PP into the microenvironment where it
becomes accessible to monocytes and Vc9/Vd2 T cells.
The Vc9/Vd2 T cell response to phagocytosed bacteria is
HMB-PP dependent but largely independent of other
pathogen-associated molecular patterns
In order to assess the clinical relevance of our findings, we
expanded our panel of bacteria by including clinical isolates of
pathogens that are frequently associated with community- and
hospital-acquired infections and pose serious threats to public
health (Table S1 in Text S1). Of note, neutrophils harboring
HMB-PP+ pathogens but not neutrophils harboring HMB-PP2
pathogens induced in Vc9/Vd2 T cells the co-expression of
CD69, TNF-a and IFN-c (Figure 7A and data not shown). This
Figure 4. Vc9/Vd2 T cells respond to bacteria upon phagocy-
tosis by neutrophils. (A) Resting neutrophils or neutrophils after
phagocytosis of M. smegmatis-gfp+ stably expressing GFP, at a
multiplicity of infection (MOI) of 10. Cells were counter-stained with
DAPI and imaged by fluorescence microscopy. Data shown are
representative from independent experiments using two different
donors. (B) Activation of Vc9/Vd2 T cells co-cultured for 20 hours with
neutrophils in the absence (medium) or in the presence of 10 nM HMB-
PP, or co-cultured with neutrophils harboring M. smegmatis-gcpE+
overexpressing HMB-PP synthase. Data shown are representative from
independent experiments using three different donors.
doi:10.1371/journal.ppat.1002040.g004
Figure 5. Vc9/Vd2 T cells show enhanced responses to
phagocytosed bacteria that overproduce HMB-PP. Dose-depen-
dent activation of Vc9/Vd2 T cells by neutrophils harboring genetically
engineered transfectants of M. smegmatis (upper panel) or L. innocua
(lower panel), in which HMB-PP accumulates intracellularly, compared
to the parental wildtype strains (wt). Data shown are mean frequencies
of CD69+ TNF-a+ Vc9/Vd2 T cells 6 SEM after 20 hours in culture, as
determined in independent experiments using three different donors.
Error bars for MOIs depict mean values 6 SEM for the true colony-
forming unit (CFU) counts of the bacterial inocula used.
doi:10.1371/journal.ppat.1002040.g005
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response was largely independent of the presence of other
pathogen-associated molecular patterns such as LPS as both
Gram-negative (Acinetobacter baumannii, Enterobacter cloacae, Klebsiella
pneumoniae, Pseudomonas aeruginosa) and Gram-positive bacteria (M.
smegmatis) capable of producing HMB-PP stimulated Vc9/Vd2 T
cells equally. Direct addition of alkaline phosphatase to these co-
cultures abrogated the HMB-PP dependent cytokine responses,
confirming soluble HMB-PP as common Vc9/Vd2 T cell
stimulator in these species (Figure 7A, Figure S4 in Text S1).
The bioactivity of culture supernatants harvested after 5 hours
from neutrophils harboring the above bacteria corresponded to
levels of 0.1–10 nM HMB-PP, as titrated against a HMB-PP
standard (data not shown). Residual levels of CD69 expression
after phosphatase treatment may have been due to incomplete
degradation of HMB-PP and to indirect stimulation of Vc9/Vd2
T cells by other microbial compounds such as LPS acting on
neutrophils or monocytes [41,42]. In contrast to HMB-PP
producing species, HMB-PP deficient Gram-negative (Chryseobac-
terium indologenes) and Gram-positive bacteria (Enterococcus faecalis, L.
innocua, Staphylococcus aureus) did not elicit Vc9/Vd2 T cells
responses above background as demonstrated by the complete
lack of TNF-a (Figure 7A, Figure S4 in Text S1) and IFN-c (data
not shown). These findings illustrate the extraordinary specificity
Vc9/Vd2 T cells for HMB-PP, even in the abundant presence of
other microbial products and despite high levels of monocyte and/
or neutrophil-derived mediators such as IL-1b, IL-6 and CXCL8
that were present in our triple co-cultures regardless of the HMB-
PP status of the phagocytosed bacteria (data not shown).
Vc9/Vd2 T cells proliferate in response to phagocytosed
bacteria in a TCR, LFA-1 and TNF-a dependent manner
cd T cells expand rapidly in acute bacterial infections [18]. We
therefore tested whether phagocytosed pathogens could induce
expansion of 5-(and 6-)carboxyfluorescein diacetate succinimidyl
ester (CFSE)-labeled Vc9/Vd2 T cells. As shown in Figure 7B,
Vc9/Vd2 T cells proliferated considerably in the presence of
supernatants derived from neutrophils harboring HMB-PP+
Enterobacter cloacae but not from neutrophils harboring HMB-PP2
Chryseobacterium indologenes or Staphylococcus aureus. Similarly to the
immediate up-regulation of CD69, TNF-a and IFN-c, the
proliferation of Vc9/Vd2 T cells in response to Enterobacter cloacae
was HMB-PP dependent and could be abrogated by alkaline
phosphatase. Expanding Vc9/Vd2 T cells also up-regulated the
high affinity IL-2 receptor, CD25 (Figure 7B) and became
responsive to exogenously added IL-2, which enhanced the
proliferative response even further (data not shown). Blocking
Figure 6. Vc9/Vd2 T cells respond, in a monocyte-dependent manner, to phosphatase-sensitive molecules released from
phagocytosed bacteria. (A) Activation of Vc9/Vd2 T cells by neutrophils harboring L. innocua wt or L. innocua-gcpE+ bacteria, in the presence (cd-
mo) or absence (cd) of monocytes. Data shown are mean frequencies of CD69+ TNF-a+ Vc9/Vd2 T cells + SEM after 20 hours in culture, as determined
in independent experiments using three different donors. (B) Activation of Vc9/Vd2 T cells in the top chamber of a transwell plate separated from
neutrophils (N) harboring L. innocua-gcpE+ in the bottom chamber, in the presence or absence of monocytes (mo). Data shown are mean frequencies
of CD69+ TNF-a+ Vc9/Vd2 T cells + SEM after 20 hours in culture, as determined in independent experiments using three different donors.
(C) Activation of Vc9/Vd2 T cells co-cultured for 20 hours with monocytes in the presence of supernatants from neutrophils harboring L. innocua wt
or L. innocua-gcpE+ bacteria that had been pretreated or not with alkaline phosphatase (AP). Data shown are representative from independent
experiments using two different donors. (D) Activation of Vc9/Vd2 T cells co-cultured for 20 hours with monocytes in the presence of 1 nM HMB-PP
or 100 mM HMB-PCP pretreated or not with alkaline phosphatase (AP). Data shown are representative from independent experiments using two
different donors.
doi:10.1371/journal.ppat.1002040.g006
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experiments demonstrated a crucial requirement of soluble and
contact-dependent signals for optimum stimulation of Vc9/Vd2 T
cells. TNF-a was recently implicated in Vc9/Vd2 T cell
proliferation in response to IPP and IL-2 [43], and blocking of
lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18)
efficiently disrupted cluster formation with monocytes [31]. Here,
both Vc9/Vd2 T cell proliferation and CD25 up-regulation in
response to supernatants derived from neutrophils harboring
HMB-PP+ Klebsiella pneumoniae (Figure 7B) or Enterobacter cloacae
(data not shown) were readily inhibited by sTNFR and anti-
CD11a antibodies but not by anti-IFN-c antibodies. Finally,
addition of anti-Vc9 antibodies completely abrogated the Vc9/
Vd2 T cell proliferation in response to HMB-PP (data not shown)
and Enterobacter cloacae supernatants (Figure S7 in Text S1),
confirming a requirement for the TCR [44]. Taken together,
our findings demonstrate that Vc9/Vd2 T cells are rapidly
activated by a broad range of HMB-PP producing pathogens,
leading to TCR, LFA-1 and TNF-a dependent cd T cell
expansion.
Acute infections caused by HMB-PP producing bacteria
are characterized by elevated numbers of activated cd T
cells
We next addressed whether the dichotomy between HMB-PP+
and HMB-PP2 pathogens in their potential to trigger cd T cells in
vitro is replicated under physiological conditions in vivo. As clinical
correlate for HMB-PP+ and HMB-PP2 infections, we analyzed
episodes of acute bacterial infections in peritoneal dialysis (PD)
patients, in whom the peritoneal catheter affords continuous and
non-invasive access to the inflammatory infiltrate (Table S2 in Text
S1). PD-associated peritonitis is characterized by a considerable
influx of neutrophils and monocytes into the peritoneal cavity
[45,46], where the two cell types may become targets for local or
infiltrating cd T cells [31,47]. Here, in a total of 24 newly recruited
patients examined on the first day of acute peritonitis (i.e. before
administration of antibiotics), both the total number and the
frequency of peritoneal Vc9/Vd2 T cells were elevated in HMB-
PP+ infections compared to HMB-PP2 infections, suggesting
increased recruitment and/or proliferation in response to
Figure 7. Vc9/Vd2 T cells respond to HMB-PP producing Gram+ and Gram2 bacteria but not to HMB-PP deficient bacteria. (A) Dose-
dependent activation of Vc9/Vd2 T cells by neutrophils harboring clinical isolates of a range of different bacteria: Gram2 HMB-PP+, Enterobacter
cloacae (two different isolates tested, A and B) and Klebsiella pneumoniae; Gram2 HMB-PP2, Chryseobacterium indologenes; and Gram+ HMB-PP2,
Enterococcus faecalis and Staphylococcus aureus; in the presence or absence of alkaline phosphatase (AP). Data shown are mean frequencies of CD69+
TNF-a+ Vc9/Vd2 T cells 6 SEM after 20 hours in culture, as determined in independent experiments using 3–5 donors. Error bars for MOIs depict
mean values6 SEM for the true CFU counts of the bacterial inocula used. (B) Proliferation after 5 days in culture and CD25 expression of CFSE-labeled
Vc9/Vd2 T cells in response to supernatants from neutrophils harboring clinical isolates of the indicated bacteria, in the presence or absence of
alkaline phosphatase (AP), soluble TNF-a receptor (sTNFR) or blocking antibodies against IFN-c or CD11a. Data shown are representative of
independent experiments using cells from at least two different donors.
doi:10.1371/journal.ppat.1002040.g007
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HMB-PP released by bacteria (Figure 8). Moreover, local activation
was evidenced by higher percentages of Vc9/Vd2 T cells expressing
CD69 in the HMB-PP+ patient group. In contrast, we did not see
any significant differences in the numbers and frequencies of
peritoneal neutrophils, monocytes/macrophages and total CD3+ T
cells, regardless of the HMB-PP status of the causative pathogen
(Figure S5 in Text S1). Similarly, while the proportion of Vc9/Vd2
T cells within peritoneal CD3+ T cells was clearly elevated in HMB-
PP+ infections, CD4+ and CD8+ T cells showed no such bias (Figure
S6 in Text S1).
Episodes of peritonitis caused by HMB-PP producing
bacteria are associated with poor clinical outcome
As Medzhitov stated recently, ‘‘inflammation is beneficial in
appropriate amounts but can easily become detrimental when
excessive because of its tissue-damaging potential’’ [48]. PD
patients constitute a particularly vulnerable group where inflam-
matory events can have profound consequences [49–51]. We
speculated that local activation of cd T cells may contribute to
inflammation-related damage and tested whether the occurrence
of clinical complications in PD patients depends on the capacity of
the causative pathogen to produce HMB-PP. Our analysis of 26
patients treated at the University Hospital of Wales, Cardiff, UK,
demonstrated that infections with HMB-PP+ bacteria were
associated with worse outcomes, evidenced as higher mortality
rates and higher incidences of technique failure (i.e., cessation of
therapy due to catheter removal, transfer to hemodialysis or
patient death), while HMB-PP2 bacteria caused milder disease
(Figure 9). Of note, we were able to validate this pattern in two
larger and entirely independent cohorts treated in Australia
(ANZDATA Registry) and at the University Hospital of North
Staffordshire, Stoke-on-Trent, UK (Figure 9). In order to rule out
that this pattern was not due to differences in Gram staining (and
hence endotoxin-related), we divided the group of HMB-PP+
bacteria further into Gram+ and Gram2 species. Our outcome
analysis demonstrates that even within the Gram+ group, bacteria
capable of producing HMB-PP were associated with worse
outcomes compared to HMB-PP2 pathogens (Figure 9), suggest-
ing that the HMB-PP producing capacity of the causative
pathogen might be of predictive value for the clinical outcome
from bacterial peritonitis (Table S3 in Text S1).
Peritoneal cd T cell frequencies and TNF-a levels might
predict clinical outcome in peritonitis patients
In order to identify potentially useful diagnostic and prognostic
biomarkers of inflammation severity and outcomes from bacterial
infection, we measured a large number of immunological
parameters. These analyses identified elevated frequencies of
peritoneal Vc9/Vd2 T cells on day 1 as possible predictor of
subsequent technique failure within three months after infection
Figure 8. Vc9/Vd2 T cell numbers and CD69 expression are
elevated in acute peritonitis caused by HMB-PP bacteria. Total
numbers and frequencies of Vc9/Vd2 T cells (% of total cells and % of all
CD3+ T cells), and expression of CD69 on peritoneal Vc9/Vd2 T cells in
patients with PD-associated peritonitis on day 1 (the day of hospital
admission with a cloudy effluent, i.e. before commencement of
antibiotic therapy), depending on whether or not the causative
pathogen was capable of producing HMB-PP.
doi:10.1371/journal.ppat.1002040.g008
Figure 9. Episodes of peritonitis caused by HMB-PP producing
bacteria are associated with poor clinical outcome. Cumulative
patient survival (left) and cumulative technique survival (right) of
patients with acute bacterial peritonitis, grouped into infections with
Gram+ HMB-PP2 (blue), Gram+ HMB-PP+ (green) or Gram2 HMB-PP+
pathogens (red); episodes caused by Gram2 HMB-PP2 pathogens were
not recorded in the patient databases. Top, PD patients admitted at the
University Hospital of Wales, Cardiff, with acute peritonitis (day 1, i.e.
first presentation with a cloudy bag). Middle, Australian PD patients
from the ANZDATA registry with first-time peritonitis. Bottom, PD
patients with first-time peritonitis treated at the University Hospital of
North Staffordshire, Stoke-on-Trent, UK. Comparisons were made using
log-rank tests.
doi:10.1371/journal.ppat.1002040.g009
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(Table 1). Similarly, expression of the activation marker HLA-DR
by peritoneal Vc9/Vd2 T cells on the day of admission was
associated with increased mortality. No other parameters tested
including the numbers and frequencies of neutrophils, monocytes
or CD4+ and CD8+ T cells reached statistical significance (data
not shown). Among soluble factors in peritoneal effluent, only
elevated levels of TNF-a on day 1 indicated higher rates of
technique failure and mortality (Table 1), while no such
correlation was seen for other cytokines and chemokines, including
GM-CSF, IFN-c, IL-1b, IL-2, IL-6, IL-10, IL-12p70, IL-17, IL-
22, CXCL8, CXCL10 and sIL-6R (data not shown).
Pre-treatment of bacteria with fosmidomycin blocks
HMB-PP production and abrogates cd T cell responses
Our findings of a rapid cd T cell response to neutrophil-
engulfed HMB-PP producing pathogens and its potential detri-
mental consequence in episodes of acute peritonitis may not only
be of diagnostic and predictive value for affected patients, they also
highlight possible new avenues of therapeutic intervention in
bacterial infections. HMB-PP is an intermediate of the non-
mevalonate pathway of isoprenoid biosynthesis, in which the first
enzymatic step catalyzed by 1-deoxy-D-xylulose-5-phosphate
reductoisomerase (Dxr) can be inhibited by fosmidomycin (Figure
S8A in Text S1), a natural antibiotic produced by Streptomyces
lavendulae [52,53]. We therefore speculated that the effect of
fosmidomycin pre-treatment of bacteria may serve a dual purpose
in treating acute infections: by directly inhibiting an essential
pathway in a broad range of pathogens and by abrogating HMB-
PP driven inflammatory responses.
Tests with selected clinical isolates of common pathogens
demonstrated that the majority of HMB-PP+ bacteria (Enterobacter
cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa) was susceptible to
overnight treatment with fosmidomycin (with the exception of
Acinetobacter baumannii as expected [54]), with a mean inhibitory
concentration (MIC) of 1–32 mg/ml depending on the strain
(Table S1 in Text S1). Of note, fosmidomycin also acted on
multidrug-resistant strains including bacteria harboring the
recently discovered ‘New Delhi’ metallo-b-lactamase 1 (NDM-1)
[55,56] (Davey MS, Tyrrell JM et al., submitted for publication). In
contrast to the efficient killing of most HMB-PP+ bacteria, the
HMB-PP2 bacteria Chryseobacterium indologenes, Enterococcus faecalis
and Staphylococcus aureus were not affected by fosmidomycin (Table
S1 in Text S1).
We next investigated the potential of short-term fosmidomycin
treatment to affect cd T cell activation by inhibiting the bacterial
HMB-PP biosynthesis. Prior exposure of bacteria to fosmidomycin
for 1 hour did not affect uptake by neutrophils as demonstrated
using Escherichia coli-gfp+ (Figure S8B in Text S1), and neither did it
affect gross bacterial viability as confirmed by re-plating treated
Enterobacter cloacae on antibiotic-free plates in order to overcome the
competitive inhibition by fosmidomycin (Figure 10A). Yet, pre-
incubation of Escherichia coli, Enterobacter cloacae and Klebsiella
pneumoniae with fosmidomycin for only 1 hour prior to phagocy-
tosis by neutrophils clearly abrogated their capacity to stimulate
Vc9/Vd2 T cells. This inhibitory effect on cd T cell responses was
evident both for activation of Vc9/Vd2 T cells in triple co-cultures
with neutrophils harboring fosmidomycin-treated bacteria
(Figure 10A and data not shown) as well as for activation (Figure
S8B in Text S1) and proliferation (Figure 10B) of Vc9/Vd2 T cells
in response to cell-free supernatants from neutrophils harboring
fosmidomycin-treated bacteria. Together these results indicate
that fosmidomycin not only has a direct antibacterial effect but
also possesses immediate anti-inflammatory properties by inhibit-
ing cd T cell-driven responses (Figure 11), thus making the non-
mevalonate pathway an attractive novel drug target for the
treatment of acute infection.
Table 1. Identification of immune markers of possible
predictive value for clinical outcome in 8 stable PD patients
and 29 PD patients with acute peritonitis (means 6 SD).
90th day technique failure
Stable
patients Survivors
Non-
survivors
Vc9+ (% of CD3+ T cells) 1.560.9 2.562.1 4.963.2*
TNF-a (pg/ml) 3.164.3 41.9653.3 128.4691.0*
90th day mortality
HLA-DR+ (% of Vd2+ T cells) 14.7610.5 11.5610.5 40.667.5***
TNF-a (pg/ml) 3.164.3 48.1660.4 148.7690.2*
Asterisks indicate significant differences between survivors and non-survivors.
doi:10.1371/journal.ppat.1002040.t001
Figure 10. Abrogation of HMB-PP dependent cd T cell
responses by fosmidomycin. (A) Activation of Vc9/Vd2 T cells co-
cultured for 20 hours with neutrophils harboring Enterobacter cloacae
pre-treated or not for 1 hour with the indicated concentrations of
fosmidomycin. The minimum inhibitory concentration (MIC) of fosmi-
domycin for this bacteria strain was 1 mg/ml, as determined by
microbroth dilution (Table S1 in Text S1). Data shown are frequencies
of CD69+ TNF-a+ Vc9/Vd2 T cells after 20 hours in culture, alongside
CFU counts of the original bacterial inocula after 1 hour treatment with
fosmidomycin, representative of independent experiments using cells
from two different donors. FACS plots show typical Vc9/Vd2 T cell
responses, representative of independent experiments using cells from
three different donors. (B) Proliferation after 5 days in culture of CFSE-
labeled Vc9/Vd2 T cells in response to supernatants from neutrophils
harboring Enterobacter cloacae pre-treated or not for 1 hour with
0.25 mg/ml fosmidomycin. Data shown are representative of indepen-
dent experiments using cells from two different donors.
doi:10.1371/journal.ppat.1002040.g010
Neutrophil-gd T Cell Crosstalk in Early Infection
PLoS Pathogens | www.plospathogens.org 9 May 2011 | Volume 7 | Issue 5 | e1002040
Discussion
Despite its relevance in early infection, the immediate crosstalk
of cd T cells, monocytes and neutrophils in the presence of
bacterial pathogens has not been addressed in detail. This is
particularly the case in humans who possess a unique cd T cell
population uniformly targeting an invariant non-self-metabolite,
HMB-PP. Previous reports already associated the activation of
Vc9/Vd2 T cells with the production of HMB-PP by microbes.
This link was mainly based on the observation that Vc9/Vd2 T
cell levels are often elevated in the blood of patients infected with
HMB-PP producing pathogens [18] and that bacterial extracts
prepared from those species activate Vc9/Vd2 T cells in vitro much
better than extracts prepared from HMB-PP deficient micro-
organisms [19,35,57]. Other investigators have speculated that
Vc9/Vd2 T cells respond in vivo toward infected host cells with
dysregulated isoprenoid metabolism leading to accumulation of
isopentenyl pyrophosphate (IPP) regardless of the presence or
absence of HMB-PP [58]. Here we unequivocally demonstrate
that Vc9/Vd2 T cells respond to live bacteria upon phagocytosis
by neutrophils, that this response is strictly HMB-PP dependent,
and that it is amplified by the presence of monocytes providing
crucial accessory signals. While it has remained puzzling how the
immune system actually ‘sees’ an intracellular metabolite that is
unlikely to be secreted or released by live micro-organisms, our
findings show that biologically relevant traces of HMB-PP escape
into the microenvironment after phagocytosis of extracellular
bacteria by neutrophils. These conditions are likely to occur
during the acute stage of the infection when Vc9/Vd2 T cells and
monocytes are co-recruited to the site of inflammation [17] where
they encounter neutrophils engaged in clearing invading patho-
gens (Figure 11).
The present findings explain how HMB-PP may become
released at the site of infection. However, the molecular
mechanism of HMB-PP recognition by Vc9/Vd2 T cells remains
poorly understood. Our observation that monocytes were required
for Vc9/Vd2 T cell responses to phagocytosed bacteria offers
important clues. Monocytes and monocyte-derived macrophages
or DCs were shown before to provide accessory help and may
constitute a pivotal trigger for Vc9/Vd2 T cell responses to
different bacterial pathogens. In the case of direct infection of
monocytic cells, HMB-PP derived from intracellular bacteria may
reach the cell surface bound to a presenting molecule [24,25,27].
In the case of extracellular bacteria, monocytes may take up or
bind soluble HMB-PP released by professional phagocytes and
present it to Vc9/Vd2 T cells (Figure 11). The HMB-PP
presenting pathway remains elusive but may involve cell surface
F1-ATPase [59], together with tight cell-cell interactions via LFA-
1/ICAM-1 [31,60], while it is independent of MHC class I, MHC
class II, b2-microglobulin or CD1 [61]. Of note, any chemical
modification of the molecular structure of HMB-PP abrogates its
bioactivity by several magnitudes, such that the closely related
natural metabolites IPP and DMAPP are .10,000 times less
active in vitro [39,40,62,63]. This is supported by our previous
[35,64,65] and present demonstration that HMB-PP deficient
bacteria (but which produce IPP and DMAPP) fail to stimulate
cytokine production by Vc9/Vd2 T cells. Treatment with
fosmidomycin or alkaline phosphatase abrogated the Vc9/Vd2
T cell responses to HMB-PP producing bacteria and emphasized
the importance of HMB-PP for the induction of IFN-c and
TNF-a. However, fosmidomycin or alkaline phosphatase treated
cultures as well as cultures involving HMB-PP deficient bacteria
did show residual levels of CD69 expression, in line with a role for
direct or indirect sensing of microbial TLR ligands [41,42,66] that
is likely to amplify the overall response. In this respect it is
intriguing that our present study identified a crucial role for TNF-
a in supporting Vc9/Vd2 T cell proliferation, a cytokine which is
readily produced not only by activated Vc9/Vd2 T cells
themselves but also by neutrophils and monocytes exposed to
Figure 11. HMB-PP dependent interaction between cd T cells, neutrophils and monocytes in acute microbial infection. Local secretion
of inflammatory chemokines leads to extravasation of neutrophils, monocytes and cd T cells toward the site of infection. Upon phagocytosis of
invading microbes, neutrophils release traces of HMB-PP into the microenvironment where it becomes ‘visible’ to cd T cells. cd T cells recognize HMB-
PP in the context of a yet unidentified presenting molecule ‘X’ and contact-dependent signals provided by monocytes. Crosstalk between the three
different cell types triggers the production of pro-inflammatory cytokines such as TNF-a, which drives local cd T cell expansion, and chemokines such
as CXCL8, which recruits further neutrophils to the site of infection. Activated cd T cells also provide survival and activation signals such as TNF-a for
newly arriving neutrophils and monocytes. This cd T cell-driven inflammatory reaction can be interrupted at various check-points as demonstrated in
the present study.
doi:10.1371/journal.ppat.1002040.g011
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microbial compounds such as LPS. This is in stark contrast to
other cytokines produced by innate immune cells such as IFN-a
and IFN-b which may induce upregulation of CD69 on Vc9/Vd2
T cells but fail to co-stimulate Vc9/Vd2 T cell proliferation [32].
Taken together, we identified an inflammatory crosstalk of Vc9/
Vd2 T cells, neutrophils and monocytes in the presence of HMB-
PP producing bacteria that can be manipulated at various check-
points: (i) the antibiotic fosmidomycin abrogates the microbial
HMB-PP production and thus renders bacterial pathogens
invisible for Vc9/Vd2 T cells; (ii) alkaline phosphatase degrades
free HMB-PP released by neutrophils into the microenvironment;
(iii) blocking antibodies against the TCR prevent the recognition of
HMB-PP by Vc9/Vd2 T cells; (iv) blocking antibodies against
CD11a disrupt the LFA-1/ICAM-1 dependent contact between
cd T cells and monocytes needed for cd T cell stimulation; (v) and
sTNFR neutralizes soluble TNF-a which is released by all three
cell types in response to microbial ligands and acts as growth factor
for Vc9/Vd2 T cells and survival factor for neutrophils (Figure 11).
How does the HMB-PP dependent crosstalk of Vc9/Vd2 T
cells, monocytes and neutrophils in vitro translate into the situation
in vivo in acutely infected patients? Studies in patients with systemic
inflammatory response syndrome suggested a significant role for
Vc9/Vd2 T cells as early responders after severe insult and
identified a correlation between Vc9/Vd2 T cell activation and
clinical scores [67]. Our own findings in patients with PD-related
peritonitis support this notion and demonstrate that the capacity of
the causative pathogen to produce HMB-PP and local infiltrates of
activated Vc9/Vd2 T cells on day 1 are indicative of acute
inflammatory responses and may predict the subsequent clinical
outcome from infection. It is becoming increasingly clear that the
nature of the infection is a major determinant of outcome, and
future interventions may well have to focus on subgroups of
patients with different forms of infection [68]. A careful re-analysis
of peritonitis outcomes from validated registry data [69–76]
confirms that HMB-PP+ bacteria cause clinically more severe
infection and emphasizes the need to pay more attention to
detailed host-pathogen interactions. Bacterial infection remains a
leading cause of morbidity and mortality worldwide, not the least
due to the alarming spread of antibiotic-resistant pathogens that is
posing an enormous challenge on clinical practice, public
healthcare and biomedical research [55,56]. In most cases,
antimicrobial treatment is largely empirical as microbiological
culture results are typically not available for 2–3 days. Moreover,
many times no organism can be identified, with rates of culture-
negative infections occasionally reaching 50% [77]. In contrast,
laboratory analyses of immune cells and/or soluble mediators may
provide valuable information within a few hours and both aid
diagnosis and refine treatment. In this respect, fosmidomycin or
related HMB-PP inhibitors might constitute useful combination
partners for antibiotic therapy especially in critical cases such as
acute peritonitis or sepsis where the intervention has to commence
before the nature of the causative pathogen is known, and where
activated Vc9/Vd2 T cells may contribute to poor clinical
outcome. Fosmidomycin targets an essential pathway in a broad
range of pathogens [54,78,79] and simultaneously abrogates Vc9/
Vd2 T cell responses [80,81]. Of note, the inhibitory effect of
fosmidomycin on the Vc9/Vd2 T cell bioactivity was detectable
after only 1 hour of treatment and well below its MIC, i.e. under
conditions that would easily be achievable in patients. Other ways
of specifically manipulating cd T cell mediated responses may
include the use of anti-cd TCR antibodies or cd TCR antagonists
such as BrH-PCP [82]. Given the importance of TNF-a for cd T
cell proliferation and the association of peritoneal TNF-a levels
with morbidity and mortality, one may also advocate the use of
TNF-a blocking reagents for the treatment of acute PD-related
peritonitis [83].
Taken together our experiments demonstrate that Vc9/Vd2 T
cells recognize with HMB-PP a small common molecule released
by the majority of invading bacteria when they become
phagocytosed by neutrophils. Stimulation of Vc9/Vd2 T cells
at the site of infection is likely to amplify the local inflammatory
response with important consequences for pathogen clearance
and the development of microbe-specific immunity. However, if
triggered at the wrong time or the wrong place, this rapid
reaction toward most bacteria may also lead to inflammation-
related damage and detrimental clinical outcome. These findings
improve our insight into the complex cellular interactions in early
infection, identify novel biomarkers of possible diagnostic and
predictive value and highlight new avenues for therapeutic
intervention.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki and under local ethical guidelines
(Bro Taf Health Authority, Wales). The study was approved by the
South East Wales Local Ethics Committee under reference
number 04WSE04/27. All patients provided written informed
consent for the collection of samples and subsequent analysis.
Patients
The Cardiff study population included 39 adult patients who
were receiving PD at the University Hospital of Wales, Cardiff,
UK, and were admitted with acute peritonitis between September
2008 and October 2010 (Table S2 in Text S1). Eight stable
patients with no infection in the previous 3 months were included
in this study as non-infected controls. In addition, microbiological
and survival data were obtained from all 739 adult patients who
were receiving PD between 1987 and 2008 at the University
Hospital of North Staffordshire, Stoke-on-Trent, UK; and from all
2,542 Australian adult patients from the Australia and New
Zealand Dialysis Transplant (ANZDATA) Registry who were
receiving PD between 2003 and 2008 (Table S2 in Text S1).
Diagnosis of acute peritonitis was based on the presence of
abdominal pain and cloudy peritoneal effluent with .100 WBC/
mm3. Infections were grouped into culture-positive and culture-
negative episodes, according to the result of the microbiological
analysis of the effluent. Bacteria species identified in culture-
positive infections were grouped into HMB-PP+ and HMB-PP2,
based on the presence or absence of HMB-PP in the microbial
metabolism [17,19]. Endpoints of outcome analyses were 14th and
90th day mortality and technique failure (catheter removal,
transfer to hemodialysis, and/or patient death). In order to rule
out a history of previous antibiotic treatment as a potentially
confounding factor, outcome studies were restricted to patients
with first-episode peritonitis, excluding cases of fungal infection or
unrecorded culture results.
Bacteria culture
Bacteria strains used in this study are listed in Table S1 in Text
S1. Mycobacterium smegmatis strains were grown aerobically at 37uC
in liquid Lemco medium (Oxoid) supplemented with 10 mg/ml
peptone, 5 mg/ml NaCl and 0.25% Tween 80 (Sigma), or on solid
Lemco plates with 15 mg/ml agar (Fisher). Listeria innocua strains
were grown aerobically at 37uC in liquid brain heart infusion
medium (Oxoid) or on agar plates. Escherichia coli laboratory strains
and multi-drug resistant clinical isolates of Acinetobacter baumannii,
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Chryseobacterium indologenes, Enterobacter cloacae, Enterococcus faecalis,
Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus
were grown in liquid LB broth and on solid Columbia blood agar
(Oxoid). Where appropriate, antibiotics were added to the
medium: M. smegmatis-gcpE+, 100 mg/ml hygromycin B; L.
innocua-gcpE+, 7.5 mg/ml chloramphenicol; E. coli-gfp+, 100 mg/ml
ampicillin (all from Sigma). Bacterial susceptibilities to fosmido-
mycin were determined by microbroth dilution method, according
to the Clinical and Laboratory Standards Institute guidelines [84].
A log 2 dilution series of 0.06 to 128 mg/ml allowed the
identification of the minimal inhibitory concentration (MIC)
where bacterial growth was absent. No defined break points have
been acknowledged for fosmidomycin [85], therefore resistance
was defined as concentrations .128 mg/ml.
Cell isolation
Peritoneal cells were harvested from chilled overnight dwell
effluents [31,47]; cell-free supernatants were stored at 270uC.
PBMC were isolated from peripheral blood of healthy volunteers
using Lymphoprep (Axis-Shield). Vc9+ T cells (.98%) were
purified from PBMC using monoclonal antibodies (mAbs) against
Vc9-PE-Cy5 (Immu360; Beckman-Coulter) and anti-PE microbe-
ads (Miltenyi). Monocytes (.98%) were purified using anti-CD14
microbeads (Miltenyi). Neutrophils (.95%) used for bacterial
phagocytosis were isolated from peripheral blood using a
Lymphoprep gradient followed by dextran sedimentation [86].
Remaining erythrocytes were lysed with ammonium chloride
solution (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA), and
neutrophils were washed in HBSS without Mg2+ and Ca2+ (Sigma)
and resuspended to a final cell concentration of 26106/ml in
HBSS with Mg2+ and Ca2+ (Sigma) supplemented with 10%
human serum. Neutrophils (.98%) used in Vc9/Vd2 T cell co-
culture experiments were isolated from peripheral blood by initial
dextran sedimentation followed by centrifugation through discon-
tinuous Percoll gradients [87]. The cell culture medium used
throughout this study was RPMI-1640 with 2 mM L-glutamine,
1% sodium pyruvate, 50 mg/ml penicillin/streptomycin and 10%
fetal calf serum (Invitrogen).
Phagocytosis of live bacteria
Single colonies were grown in culture broth for 18 hours, and
bacteria were washed in PBS and resuspended in HBSS with Mg2+
and Ca2+ supplemented with 10% human serum. Freshly isolated
neutrophils were incubated with bacteria at a multiplicity of
infection (MOI) of 0.1–100 bacteria per neutrophil for 30–60 min
at 37uC, with gentle shaking. In some experiments, bacteria were
pre-treated with 0.5–25 mg/ml fosmidomycin for 1 hour prior to
phagocytosis. Actual MOIs of all bacterial inocula used were
determined by plating out serial dilutions on agar plates and
expressed as colony forming units (CFU) per neutrophil. Non-
phagocytosed bacteria were washed off three times. For micro-
scopic analyses, neutrophils harboring GFP-expressing bacteria
were washed, counterstained with DAPI (Sigma) and fixed in 2%
paraformaldehyde. Images were acquired on a Nikon Eclipse 80i
fluorescence microscope equipped with a Nikon DXM 1200F
camera and processed with Adobe Photoshop. For the generation
of cell-free supernatants, neutrophils pre-incubated with bacteria
as described above were cultured for 5 hours in complete RPMI-
1640. Supernatants were then harvested and cells removed by
centrifugation at 12,000 g for 10 min. Samples were stored at
220uC and thawed a maximum of 5 times. For some experiments,
neutrophil supernatants were treated with 0.015 U/ml shrimp
alkaline phosphatase for 30 min at 37uC.
Triple co-cultures of neutrophils, monocytes and cd T
cells
Unless indicated otherwise, neutrophils were co-cultured for
20 hours in complete RPMI-1640 medium (further supplemented
with 8 mg/ml colistin (Sigma) for assays involving multi-drug
resistant clinical isolates) with autologous monocytes and cd T cells
at a ratio of 10 neutrophils and 1 monocyte per 1 cd T cell
(10:1:1), in the absence or presence of 0.015 U/ml shrimp alkaline
phosphatase (Roche). Proliferation assays using cd T cells that had
been pre-labeled with CFSE (Molecular Probes) were incubated
for 4–6 days. Controls included co-cultures in the absence or
presence of 1–100 nM synthetic HMB-PP [40] or 1–100 ng/ml
LPS from Salmonella abortus equi (Sigma). In transwell experiments,
neutrophils were separated from cd T cells by 0.4 mm pore
polycarbonate membranes (Fisher Scientific). Cell-free superna-
tants derived from neutrophils after phagocytosis of bacteria were
tested in monocyte-cd T cell co-cultures (1:1) at a dilution of 1 in 3.
Blocking reagents used were anti-IFN-c (25718; R&D Systems);
anti-CD11a (TS1/22) from Dr Ruggero Pardi (DIBIT-Scientific
Institute San Raffaele, Milano, Italy); and sTNFR p75-IgG1 fusion
protein (Enbrel; Amgen); alone or in combination at 10 mg/ml
each. Anti-TCR-Vc9 (Immu360; Beckman Coulter) was used at
1.25 mg/ml.
Flow cytometry
Cells were acquired on an eight-color FACSCanto II (BD
Biosciences) and analyzed with FloJo 7.6 (TreeStar), using
monoclonal antibodies against CD3 (UCHT1), CD15 (HI98),
CD25 (M-A251), CD62L (DREG-56), CD69 (FN50), CD86
(2331) and HLA-DR (L243) from BD Biosciences; TCR-Vc9
(Immu360) and CD40 (mAB89) from Beckman Coulter; and
CD11b (ICRF44) and CD14 (61D3) from eBioscience; together
with appropriate isotype controls. Cells of interest were gated
based on their appearance in side scatter and forward scatter area/
height, exclusion of live/dead staining (fixable Aqua; Invitrogen)
and surface staining: CD32 CD142 CD15+ neutrophils, CD32
CD14+ CD152 monocytes, and CD3+ Vc9+ cd T cells. Apoptotic
cells were identified using Annexin V (BD Biosciences). For
detection of intracellular cytokines, 10 mg/ml brefeldin A (Sigma)
was added to cultures 5 hours prior to harvesting. Surface-stained
cells were labeled using the Fix & Perm kit (eBioscience) and
monoclonal antibodies against IFN-c (45.15; BD Biosciences) and
TNF-a (188; Beckman Coulter).
Culture supernatants and effluent samples
Soluble cytokines in cell culture supernatants were detected
using ELISA kits for IL-1b, IL-6 and IL-17 (R&D Systems); and
IFN-c, TNF-a and CXCL8 (BD Biosciences). All samples were
measured in duplicate on a Dynex MRX II reader. Cell-free
peritoneal effluents were analyzed on a SECTOR Imager 600
(Meso Scale Discovery) for TNF-a, GM-CSF, IFN-c, IL-1b, IL-2,
IL-6, IL-10, IL-12p70, CXCL8 (IL-8) and soluble IL-6 receptor
(sIL-6R). In addition, IL-17, IL-22 and CXCL10 in peritoneal
effluents were measured in duplicate on a Dynex MRX II reader,
using conventional kits (R&D Systems).
Statistical analysis
Data were analyzed using two-tailed Student’s t-tests (GraphPad
Prism 4.0), and considered significant as indicated in the figures
and tables: *, p,0.05; **, p,0.01; ***, p,0.001. Cumulative
survival curves as a function of time were generated using the
Kaplan-Meier approach and compared using the log rank test
(SPSS 16.0).
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